Vaccines have been in use since decades to provide immunological responses against diseases. A conventional vaccine is a biological preparation of weakened or attenuated, killed forms of a microbe or one of its cellular components, while a DNA vaccine is composed of genetically engineered DNA. When a DNA vaccine is injected into the cells of an organism, it stimulates organism’s immune system to produce immunity against the encoded antigens. DNA vaccines have a number of advantages over conventional vaccines such as when a conventional vaccine is administered, it activates only antibody reaction while a DNA vaccine activates antibody as well as cell mediated reaction. This new generation vaccine also offers fewer side effects compared to conventional vaccines.
The market for DNA vaccines is segmented into human DNA vaccines and animals DNA vaccines market. Currently there are no approved DNA vaccines for human but more than 100 products are under clinical trial for a variety of diseases including HIV infection, cancer and infectious diseases. Pennsylvania based Inovio Pharmaceuticals has it’s Syncon brand of vaccines in clinical trial for a variety of cancers and infectious diseases. On the other hand there are three DNA vaccines approved for animal health. The first vaccine was approved in the year 2005 for use in horses against West Nile Virus. Some of the pipeline DNA vaccines developed by Vical are Apex IHN for infectious hematopoietic necrosis virus and ONCEPT for melanoma in dogs.
The global market for DNA vaccines is growing impressively under the influence of advantages associated with this new generation of vaccines such as fewer side effects, ease of development and lower cost and continued development in biotechnology arena. The human health segment is expected to grow at relatively higher CAGR compared to animal health segment. Some of the notable companies operating in this market are Novartis Animal Health, Inovio Biomedical Corp, Merck & Co., Dendreon Corporation, Astellas Pharma, Vical, Sanofi and Tekmira Pharmaceuticals.
This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Rest of the World
This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a technological growth map over time to understand the industry growth rate
- It provides a seven-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Note : All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Transparency Market Research.